{"subscriber":false,"subscribedOffers":{}} New Federal Guidelines For Physician–Pharmaceutical Industry Relations: The Politics Of Policy Formation | Health Affairs

Cookies Notification

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more.
PUBLISHED:No Accesshttps://doi.org/10.1377/hlthaff.24.4.949

In October 2002 the federal government issued a draft “Compliance Program Guidance for Pharmaceutical Manufacturers.” The draft Guidance questioned the legality of many arrangements heretofore left to the discretion of physicians and drug companies, including industry-funded educational and research grants, consultantcies, and gifts. Medical organizations and drug manufacturers proposed major revisions to the draft, arguing that current practices were in everyone’s best interest. To evaluate the impact of their responses, we compare the draft, the changes requested by industry and organized medicine, and the final Guidance document (issued in April 2003). We also explore the implications—some intended, others unanticipated—of the final document.

Loading Comments...